Undetectable levels achieved for nearly nine months in phase 1 trial A novel short-interfering RNA (siRNA) therapy known as lepodisiran reduced levels of lipoprotein(a) (Lp(a)) below the lowest limit of quantitation for nearly nine months in a first-in-human phase 1 trial. The study, presented by Steven Nissen, MD, in a late-breaking science session at the American
A single infusion of a CRISPR-based gene editing therapy significantly reduced LDL-C and PCSK9 levels in patients with heterozygous familial hypercholesterolemia (HeFH), based on findings from the VERVE-101 trial presented Nov. 12 at AHA 2023. In presenting the findings, Andrew Bellinger, MD, PhD, said they provide the first proof-of-concept for in vivo DNA base editing in humans.
Semaglutide 2.4 mg (Wegovy®) cardiovascular outcomes data presented at American Heart Association Scientific Sessions and simultaneously published in New England Journal of Medicine At the American Heart Asoociation annual Scientific Session were announced the primary results of SELECT, its landmark phase 3 cardiovascular outcomes trial investigating the effects of once-weekly semaglutide 2.4 mg (Wegovy®) in
Millions of people with normal blood pressure may be misclassified as having blood pressure that is too high because of improper positioning when measurements are taken, new research suggests. Guidelines from the American Heart Association and American College of Cardiology call for a patient to be seated in a chair with feet flat on the
Scientists have long sought to understand how certain animals, such as zebrafish, are able to regrow nerve fibers and regain lost motor function after spinal cord injury. In humans, these injuries are irreparable and result in permanent loss of function, such as paralysis. An international team led by Daniel Wehner of the Max Planck Institute
The work of the COVID Moonshot Consortium is being published in the prestigious journal Science on 10 November, revealing their discovery of a potent SARS-CoV-2 antiviral lead compound. It also reflects on the success of its open science approach in launching a patent-free antiviral discovery program to rapidly develop a differentiated lead in response to
The U.S. Food and Drug Administration approved Adzynma, the first recombinant (genetically engineered) protein product indicated for prophylactic (preventive) or on demand enzyme replacement therapy (ERT) in adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP), a rare and life-threatening blood clotting disorder. “The FDA remains deeply committed in our efforts to help facilitate
November the 10th a panel of international experts representing the World Health Organization’s Guideline Development Group has updated its guidance on treatments for patients with COVID-19. The new recommendations published by The BMJ are part of a living guideline, developed by the World Health Organization with the methodological support of MAGIC Evidence Ecosystem Foundation, to provide up
Cardiovascular, kidney and metabolic health measures included in new PREVENT risk calculator, detailed in a new American Heart Association Scientific Statement Statement Highlights: A new calculator estimates a person’s risk for cardiovascular disease (CVD) over the next 30 years by combining measures of cardiovascular, kidney and metabolic health for the first time, according to a
Gait impairment can be a significant challenge as Parkinson’s disease (PD) advances, with balance problems, frequent falls, and freezing of gait impeding quality of life. Often these challenges do not respond to increased amounts of PD medication or deep brain stimulation (DBS). In recent years, electrical stimulation of the spinal cord has been a research
